Comparison of 1st Generation and 2nd Generation High Dose GcMAF

Therapy | Treatment

GcMAF (Gc Protein derived
Macrophage Activating Factor)

For the treatment for cancer, HIV and immune system diseases.

Comparison of 1st and 2nd Generation GcMAF



Concentration of 1st generation and Second Generation GcMAF

First Generation GcMAF vs Saisei Mirai Second Generation GcMAF concentration



First Generation GcMAF

Dr Nobuto Yamamoto
Dr Nobuto Yamamoto
  • Developed by Dr Yamamoto in 1991
  • Low concentration (100 ng/0.25 ml, 1 dose)
  • Low stability at room temperature and when refrigerated
  • Gc protein isolated from serum using 25-(OH) Vitamin D3 Affinity Column, making the GcMAF unstable
  • Sterilized using 0.22 micron sterile filtration system
  • Tokushima University conducts experiments with 1st Generation and 2nd Generation GcMAF

Goleic GcMAF, GcMAF with oleic acid, is simply first generation GcMAF with some added components but still having the low concentration of the original first generation GcMAF developed over 20 years ago. Due to limited testing and clinical use, the efficacy of Goleic GcMAF is unknown.



Second Generation GcMAF

Dr Hitoshi Hori, University of Tokushima Dr Yoshihiro Uto, University of Tokushima Dr Kentaro Kubo, Saisei Mirai
Dr Hitoshi Hori, University of Tokushima Dr Yoshihiro Uto, University of Tokushima Dr Kentaro Kubo, Saisei Mirai
  • 2nd Generation High Dose GcMAF Developed by the University of Tokushima and Saisei Mirai in 2011
  • New patented production process
  • High concentration (1500 ng/0.5 ml, 1 dose)
  • Very high macrophage activating activity
  • Much higher stability even at room temperature *
  • Demonstrated in vitro to increase the rate of maturation of Dendritic Cells (DCs).
  • Sterilized using 0.22 micron sterile filtration system

* Second Generation GcMAF is best stored refrigerated and will stay fully active for over 1 year. Stability tests indicate that 2nd Generation GcMAF is very temperature stable and retains maximum activity even after 4 weeks at room temperature and 1 week at 40 °C (104 °F).



GcMAF timeline


1991 Dr Yamamoto developed GcMAF
1992 Dr Yamamoto visited Dr Hori at Tokushima University
GcMAF research started at Tokushima University
1998 Dr Uto joined Dr Hori's GcMAF research team
2002 First research papers published on GcMAF in the journals Biotherapy and Comparative Biochemistry & Physiology
2010 Tokushima University began collaborating with Saisei Mirai to develop Second Generation High Dose GcMAF
2011 Second Generation GcMAF produced in our Cell Processing Center (CPC) for patients. Start of clinical use.
2013 Two research papers published in Anticancer Research by Saisei Mirai & Tokushima University
2013 Over 1000 patients treated with Saisei Mirai GcMAF
2014 New research paper published in Anticancer Research by Saisei Mirai & Tokushima University

If you wish to purchase GcMAF therapy or make an enquiry, please contact us with details of your disease, current treatment and the quantities of Gc-MAF you require.



News

Heart Pharmacy website gcmaf.co.jp is now open

Purchase your Colostrum MAF here using PayPal or credit card.

Heart Pharmacy website


2016 Integrative Medical Therapies Conference - Osaka, Japan

Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.

2016 Integrative Medical Therapies conference - Osaka, Japan


Genostics Conference - Sydney, Australia

24-SEP-2016
Dr Toshio Inui

Genostics official website


Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia


22-JUL-2016
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.



International Pharmacy Conference

14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.



New New research papers published by Saisei Mirai in Anticancer Research available online.

Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis (PDF)
ANTICANCER RESEARCH 36: 3771-3774 (2016)

Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis

Research paper
2016 Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields (PDF)
ANTICANCER RESEARCH 36: 3767-3770 (2016)

Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields

Research paper
2016 Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors (PDF)
ANTICANCER RESEARCH 36: 3619-3624 (2016)

Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.

Research paper
2015 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (PDF)
Anticancer Res August 2015 35 (8) 4545-4549

Conference presentation - 10th International Congress for Medical Laser Applications, Germany

13-JUN-2015
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui

Clinical application of Second Generation GcMAF and oral GcMAF
ISLA website

Conference presentation - 9th International Congress for Medical Laser Applications, Germany

29-JUN-2014
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)

Dr Toshio Inui

Dr Toshio Inui Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections

Conference presentation - The 17th Annual Meeting of The Society of Biotherapeutic Approaches, Fukuoka University

7-DEC-2013
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT

Dr Toshio Inui

Dr Toshio Inui Case Report - A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.

Research paper
2013 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity (PDF)
Anticancer Res July 2013 33 (7) 2881-2885

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Research paper
2013 Clinical Experience of Integrative Cancer Immunotherapy with GcMAF (PDF)
Anticancer Res July 2013 33 (7) 2917-2919

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Nature Outlook sponsored article

For more details on GcMAF see our GcMAF page.



Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.

Stability of GcMAF in Serum report Stability of GcMAF in Serum report

The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.

See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.


Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.


University of Tokushima, Institute of Technology and Science, Laboratory Research

Our research group:


Imagin-K

Contact us
GcMAF
Treatments and therapies
Contact us

Saisei Mirai Clinics
Kobe Saisei Mirai Clinic
  • Cancer
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
Kobe Saisei Mirai Clinic

Boeki Center Building
23rd Floor
5-1-14 Hamabetori Chuo-ku
Kobe-shi
Hyogo-ken 651-0083
Japan


Inui Cancer
Immunotherapy Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
Inui Cancer Immunotherapy Clinic

6-14-17 Kindachou
Moriguchi-shi
Osaka 570-0011
Japan
TEL: +81 (0)6-6902-5251
FAX: +81 (0)6-6902-7133

Inui Cancer Immunotherapy Clinic

Keihan Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
  • Anti-aging
Saisei Mirai Keihan Clinic

Nature 21 Building
2nd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan
TEL: +81 (0)6-6902-1001


R Future Cancer Int'l Clinic
  • Cancer
R Future Cancer Int'l Clinic

ORE Hiroo Building
7th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


R Science Clinic
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
R Mirai Clinic

ORE Hiroo Building
6th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


Immunotherapy Lab
  • Cell Processing Center
Immunotherapy Lab

Nature 21 Building
3rd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan